Finally, we examined possible benefits afforded by a combination therapy, daily intraperitoneal injections of the mTOR inhibitor rapamycin from P100 to P168 in progeria mice that received lonafarnib daily from P21 to P168 via the soft chow (Figure 2A). The gene discussed is MTOR; the disease is progeroid syndrome.